PriceTargets.com logo

Cadrenal Therapeutics - CVKD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.50
  • Forecasted Upside: -78.47%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$16.26 As of 10/30/2024 03:52 PM ET
▲ +0.72 (4.63%)

This chart shows the closing price for CVKD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cadrenal Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVKD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVKD

Analyst Price Target is $3.50
▼ -78.47% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Cadrenal Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a -78.47% upside from the last price of $16.26.

This chart shows the closing price for CVKD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Cadrenal Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00
12/18/2023Noble FinancialInitiated CoverageOutperform$4.00
11/20/2023HC WainwrightReiterated RatingBuy$3.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cadrenal Therapeutics logo
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Read More

Today's Range

Now: $16.26
Low: $15.18
High: $16.49

50 Day Range

MA: $11.47
Low: $6.85
High: $17.26

52 Week Range

Now: $16.26
Low: $5.40
High: $32.55

Volume

34,616 shs

Average Volume

26,695 shs

Market Capitalization

$260.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Cadrenal Therapeutics?

The following sell-side analysts have issued reports on Cadrenal Therapeutics in the last year: HC Wainwright, and Noble Financial.
View the latest analyst ratings for CVKD.

What is the current price target for Cadrenal Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Cadrenal Therapeutics in the last year. Their average twelve-month price target is $3.50, suggesting a possible downside of 78.5%. Noble Financial has the highest price target set, predicting CVKD will reach $4.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Cadrenal Therapeutics in the next year.
View the latest price targets for CVKD.

What is the current consensus analyst rating for Cadrenal Therapeutics?

Cadrenal Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CVKD will outperform the market and that investors should add to their positions of Cadrenal Therapeutics.
View the latest ratings for CVKD.

What other companies compete with Cadrenal Therapeutics?

Other companies that are similar to Cadrenal Therapeutics include Mesoblast, Arcutis Biotherapeutics, Applied Therapeutics, CARGO Therapeutics and Phibro Animal Health. Learn More about companies similar to Cadrenal Therapeutics.

How do I contact Cadrenal Therapeutics' investor relations team?

The company's listed phone number is 904-300-0701 and its investor relations email address is [email protected]. The official website for Cadrenal Therapeutics is www.cadrenal.com. Learn More about contacing Cadrenal Therapeutics investor relations.